Identification of bacterial contaminants in polyherbal medicines used for the treatment of tuberculosis in Amatole District of the Eastern Cape Province, South Africa, using rapid 16S rRNA technique by Elizabeth Bosede Famewo et al.
RESEARCH ARTICLE Open Access
Identification of bacterial contaminants
in polyherbal medicines used for the
treatment of tuberculosis in Amatole
District of the Eastern Cape Province, South
Africa, using rapid 16S rRNA technique
Elizabeth Bosede Famewo, Anna Maria Clarke and Anthony Jide Afolayan*
Abstract
Background: Polyherbal medicines are used for the treatment of many diseases in many African and Asian
communities. With the increasing use of these remedies, several investigations have shown that they are associated
with a broad variety of residues and contaminants. This study investigates the presence of bacteria in the polyherbal
medicines used for the treatment of tuberculosis (TB) in the Eastern Cape Province of South Africa.
Methods: Bacterial DNA was extracted from the polyherbal medicines, and a fragment of the bacterial 16S
rRNA gene was amplified by PCR with universal primers 27F and 518R. The amplicons were visualised on
agarose gel electrophoresis, followed by end repair and adaptor ligation. They were further purified and
quantified using Library Preparation kit NEBNext® UltraT DNA Library Prep Kit for Illumina, and the amplicons
were run on illumina’s MiSeq platform.
Results: Different bacterial species were identified in all each of the polyherbal medicines. Generally, the most
prominent and common bacteria recovered from all the samples were Bacillus sp., Enterobacter sp., Klebsiella
sp., Rahnella sp., Paenibacillus sp., Clostridium sp. and Pantoea sp. Others are Pseudomonas sp., Raoultella ornithinolytica,
Salmonella enterica and Eubacterium moniliforme.
Conclusions: This study, thus, revealed the presence of pathogenic and non-pathogenic bacteria in the polyherbal
medicines used for the treatment of tuberculosis in the study area. The implications of the findings are discussed in
relation to the health care of the patients of tuberculosis in the study area, having in mind that they are
immunocompromised individuals.
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Background
Polyherbal medicines have been used for various thera-
peutic purposes as far back as the origin of mankind. In
South Africa, it is estimated that three million people
currently use herbal remedies (polyherbal medicines) for
their health care purposes especially in the treatment of
diarrhoea, diabetes, stomach illnesses, wound infections
and tuberculosis [1–3].
About 1 % of the South Africa population is estimated
to develop tuberculosis yearly [4]. The country accounts
for one quarter of the global burden of HIV-associated
tuberculosis (TB) [5]. This is stimulated by the high
rates of latent tuberculosis infection and the increase in
the prevailing rates of infection [4]. In fact, about 50 %
of people among the age group 15 and 77–89 % of
adults have evidence of latent TB infection [6, 7]. The
use of the current drug regimen combinations for TB is
limited due to patients’ non-compliance, which has
resulted in the rise of strains that are resistant to some
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or the entire first and second-line antibiotics [8]. The
emergence of multi-drug resistant tuberculosis (MDRTB),
extensively drug resistant tuberculosis (XDRTB), and to-
tally drug resistant tuberculosis (TDR) has exacerbated
the global health problem [9, 10]. Due to the high resist-
ance of M. tuberculosis to commonly prescribed antimi-
crobials, relatively high cost and limited access to
synthetically derived drugs, most communities especially
in Africa still rely on the use of polyherbal medicine for
the treatment of their ailments [11, 12]. Yet, these medi-
cines have been reported to contain a number of microbial
and heavy metal contaminants [13–16].
Medicinal herbs frequently harbour a large number of
microbes originating from the soil, and these microor-
ganisms normally adhered to leaves, stems, flowers,
seeds and roots of plants [17]. The contamination of
herbal products with Enterobacteriaceae, Bacillus spp.,
Salmonella spp., Staphylococcus aureus, Penicillium spp.
and Aspergillus spp. have been reported by [18]. Also,
elevated levels of bacterial and fungal contaminants,
such as Escherichia coli, yeast, Penicillium spp., Aspergil-
lus and Fusarium, were observed in herbs and spices by
[14, 19, 20]. The presence of these contaminants in the
herbal products might adversely affect the health status
of the consumers due to their immunocompromised
conditions. Microbial infections have posed a health
problem throughout the world, thus, the safety of the
consumers of herbal products is of utmost importance.
To the best of our knowledge, the microorganisms
present in some of the polyherbal medicines used for
the treatment of TB in Amathole District Municipality
of the Eastern Cape Province have not been investi-
gated despite the mass consumption of the medicines.
Most of these polyherbal remedies are prepared in the
form of concoctions or infusions and are left at room
temperature over a long period of time depending on
how rapid the patients respond to treatment. During
this period, the mineral elements present in these rem-
edies may facilitate the growth of microorganisms.
Thus, this study therefore aimed at identifying different
bacteria present in some of the polyherbal medicines




A total of nine polyherbal medicines used for the treat-
ment of TB were purchased from the traditional herbal
sellers in five communities, namely East London (EL),
King Williams Town (KWT), Hogsback (HB), Alice (AL)
and Fort Beaufort (FB) as shown in Fig. 1. Each remedy
was labelled and coded according to the place of collec-
tion, viz: King Williams Town site A (KWTa), King
Williams Town site B (KWTb), King Williams Town site
C (KWTc), Hogsback first site (HBfs), Hogsback second
site (HBss), Hogsback third site (HBts), East London (EL),
Alice (AL) and Fort Beaufort (FB). The small number of
remedies obtained in this study was due to the fact that
only a few traditional healers treat and sell the remedies
for TB. They claim to have acquired the knowledge from
their ancestors, and this knowledge is been transferred
from one generation to another. The samples were then
transported to Medicinal Plants and Economic Develop-
ment (MPED) Research Centre for analysis.
DNA extraction
The total bacterial DNA was extracted in a clean and
sterilized environment using ZR Fungal/Bacterial
MiniPrep™ Kit (Zymo Research, USA). The method of
[21] with slight modification was used for the extraction.
One millilitre of each sample was pipetted into sterile
eppendorff tubes and centrifuged at 12,500 rpm for
10 min. The supernatant was discarded, and the cell
pellets were collected. The protocol in the extraction kit
was followed.
PCR amplification of bacterial DNA
Polymerase chain reaction (PCR) was performed using
the extracted DNA from each of the samples. The bac-
terial 16S rRNAs were amplified using the oligonucleo-
tide primers 27F (5′-GGT AGA GTT TGA TCC TGG
CTC AG-3′) and 518R (5′-ATT ACC GCG GCT GCT
GG-3′). The 16S rRNA gene contains nine variable
regions (designated V1 to V9) of which we chose the
V1-V3 regions, which has previously proven useful in
research-oriented metagenomic surveys [22]. A total re-
action volume of 25 μL was used, which contained
12.5 μL Master Mix (Thermo Scientific, EU Lithuania),
1 μL each of 10 μM of both forward and reverse primer
solutions (Inqaba Biotech, SA), 5.5 μL of nuclease free
water and 5 μL template DNA. Reactions was performed
in the thermocycler (Bio-Rad Mycycler, USA) using
the following cycling conditions: initial denaturation
at 94 °C for 1 min, followed by 30 cycles of denaturation
at 94 °C for 1 min, annealing at 58 °C for 1 min, extension
at 72 °C for 1.5 min and final extension at 72 °C for
10 min [23]. In order to confirm the products size, 5 μL of
the amplicons was analysed by gel electrophoresis in 1 %
agarose (Merck, SA) stained with 3 μL ethidium bromide
(Sigma-Aldrich, USA). A 100 bp DNA ladder for 16S
rRNA (Thermo Scientific, (EU) Lithuania) was included
for band size estimation purposes. All gels were run in
0.5X TBE buffer at 95 V for 1 h and visualised by UV
trans-illumination (Alliance 4.7, France).
Purification of 16S rRNA gene amplicons and sequencing
The bacterial 16S rRNA gene amplicons were purified with
the Zymoclean™ Gel DNA Recovery kit (ZymoResearch
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Corporation, Irvine, USA) and quantified using NanoDrop
Fluorospectrometer ND3300 fragment size (Agilent Bioa-
nalyzer 2100) prior sequencing. Followed by end repair
and adaptor ligation and quantification of each library
using Library Preparation kit (NEBNext® UltraT DNA
Library Prep Kit for Illumina), before running them on
illumina’s MiSeq platform following the amplicon sequen-
cing protocol [24].
Results
Bacterial families and species identified in the remedies
The findings of this study revealed the presence of both
pathogenic and non-pathogenic bacteria in the polyher-
bal medicines used for the treatment of tuberculosis in
the Eastern Cape Province of South Africa. All the iden-
tified bacteria in the therapies belong to 12 families.
Only one of the families could not be identified (Fig. 2).
However, the prevalent families in all the polyherbal
medicines are the Enterobacteriaceae, Bacillaceae and
Paenibacillaceae (Fig. 2).
While the majority of the bacteria identified in KWTa
remedy are Enterobacteriaceae (68 %), others were Bacil-
laceae (23 %), with 9 % remaining unknown (Fig. 3a). In
the same vein, Enterobacteriaceae are the dominant
organisms in KWTb remedy and only 8 % remaining un-
known (Fig. 3b). The family Bacillaceae dominate KWTc
therapy (66 %), whereas only 3 % of the bacteria are
unknown (Fig. 3c). The identities of the majority of bac-
teria present in the herbal medicines sourced from AL
and EL were unknown (84 and 86 %, respectively), with
the remaining bacteria belonging to 16 and 5 families in
AL and EL samples, respectively (Figs. 3d, e). A high
number of bacteria identified in FB belong to Paenibacil-
laceae (98 %) as against a few other remedies where their
population is insignificant (Fig. 3f ). Similarly, HBfs, HBss
and HBts remedies were dominated by Enterobacteria-
ceae (Figs. 3g–i).
This study further investigated the bacterial species
present in each of the polyherbal medicines. The overall
blast output revealed that these polyherbal remedies
are contaminated with different bacterial genera and
species including Bacillus sp., Klebsiella sp., Rahnella
sp., Paenibacillus sp., Enterobacter sp., Pantoea sp.,
Clostridium sp., and a few unknown (Table 1). Some of
these bacteria that are clinically pathogenic to human
include Raoultella ornithinolytica, Rahnella aquatilis,
Fig. 1 Map of Amathole District Municipality
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Bacillus anthracis, Bacillus cereus, Salmonella enteric,
Enterobacter cloacae, Klebsiella oxytoca and Klebsiella
pneumonia. Others such as Enterobacter asburiae,
Paenibacillus polymyxa, Pantoea rwandensis, Klebsiella
variicola and Pseudomonas sp. are opportunistic patho-
gens causing opportunistic infections in individuals
with impaired immunity.
Discussion
The use of polyherbal medicines for the treatment of
various diseases is still a significant practice in the devel-
oping countries including South Africa. With the popu-
larity and global market expansion, the safety of herbal
products has become a major concern to public health
[25]. In this study, all the polyherbal therapies used for
the treatment of tuberculosis are orally consumed in the
form of water-extracted remedies. Naturally, the ingredi-
ents used for the preparation of these remedies are not
usually sterilized before soaking in water, hence the pres-
ence of different bacteria species and families identified
in the polyherbal medicines. The main source of con-
tamination could be from the soil, water, plant or other
raw materials and the containers used. Since these
remedies are not prepared in a sterile manner, another
possible source of contamination could be contaminants
from the personnel(s), unhygienic production condi-
tions, during harvesting, drying and storage. In addition,
environmental factors such as temperature, humidity
and extent of rainfall during pre-harvesting and post-
harvesting periods can influence the microbial contam-
ination of these medicinal herbal [26].
The presence of Bacillaceae, such as B. cereus and B.
anthracis, and Enterobacteriaceae including R. ornithino-
lytica, Rahnella sp., Klebsiella sp. and Enterobacter sp.
in these polyherbal medicines is a cause for concern.
Some of these bacteria are pathogenic to humans while
others are opportunistic pathogens (Table 1) but could
be serious public health hazard causing opportunistic
infection and reduces the immunity of the immune-
suppressed consumers. R. ornithinolytica (formerly named
Klebsiella ornithinolytica) was identified in KWTa remedy.
This bacterium is Gram-negative, non-motile, encapsu-
lated and aerobic bacillus [27]. Though an uncommon
human pathogen, about 86 infectious cases of this organ-
ism have been reported [28]. This pathogen has been
linked to bacteremia [29, 30], sepsis [31], acute suppur-
ation of the pancreatic duct [32], soft tissue infection
[33], enteric fever [34], renal cysts [35] and urinary
tract infection [36]. Also, it expresses chromosomal
class A β-lactamases, which confer resistance to ampicillin
and other aminopenicillins [28].
R. aquatilis was identified in AL remedy, KWTa, KWTb
and KWTc remedies (Table 1). The bacterium is a faculta-
tively anaerobic, nitrogen-fixing and Gram-negative rod-
shaped organism. It has been reported to cause infections
such as bacteremia, sepsis, respiratory infection, urinary
tract infection and wound infections most especially in
immune-suppressed individuals [37, 38]. Also, about 18
cases of human infection caused by R. aquatilis has been
reported, and majority of these infections were accompan-
ied by diabetes mellitus, alcoholism, cancer and AIDS
[38]. The presence of this bacterium in the polyherbal
remedies is a cause for concern considering the immuno-
compromised status of the patients.
Bacillus species such as Bacillus cereus, B. anthracis
and B. subtilis were also identified in the polyherbal
remedies. Bacillus cereus is a Gram-positive, aerobic-to-
facultative, spore-forming rod bacterium bearing close
phenotypic and genetic relationships to several Bacillus
species most especially B. anthracis [39]. This bacterium
Fig. 2 Percentage occurrence of each bacteria family identified in all the polyherbal remedy






Fig. 3 Relative frequencies of contaminating organisms in each polyherbal remedy
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Table 1 Pathogenic and non-pathogenic bacterial species identified metagenomically from the polyherbal medicines used for the treatment of tuberculosis in the Eastern Cape
Province of South Africa
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Polyherbal medicines were collected from the following: KWTa King Williamstown site A, KWTb King Williamstown site B, KWTc King Williamstown site C, AL Alice, EL East London, FB Fort Beaufort, HBft Hogsback first
treatment, HBst Hogsback second treatment, HBtt Hogsback third treatment
– absent, *pathogenic to human, a Enterobacteriaceae, b Bacilliaceae, n non-pathogenic, c unclassified bacteria, e Clostridiaceae, f Oxalobacteraceae, g Mycobacteriaceae, h Paenibacillaceae, i Streptomycetaceae,
















is an emerging human food-borne pathogen. B. cereus
has been reported to be associated with severe local and
systemic human infections such as endophthalmitis,
pneumonia, lung infections, bloody diarrhoea, gastro-
enteritis and meningitis, posing a serious public health
problem [40, 41]. The pathogenicity of B. cereus depends
on its ability to colonise, persist and subsequently invade
the host tissues [42]. The ability of this bacterium to
produce emetic toxins has been also associated with
gastro- and non-gastrointestinal infections [43].
B. anthracis is an obligate pathogen that infects many
vertebrates. It is the causative agent of anthrax. Anthrax
is an infectious disease that can infect humans in three
different ways, namely cutaneous anthrax, inhalation an-
thrax and gastrointestinal anthrax [44]. The presence of
this bacterium in the remedies could be due to the avail-
ability of its endospores in the soil where the herb ingre-
dients are harvested. The presence of Bacillus sp. in
these remedies poses great risks to the consumers.
Klebsiella species are Gram-negative, non-motile and
usually encapsulated rod-shaped bacteria [45]. Species
of this genus have been increasingly associated with
hospital infections [46]. They are common pathogens
of nosocomial pneumonia, septicaemia, urinary tract
infection, wound infections, intensive care unit infec-
tions and neonatal septicaemias [45]. K. pneumoniae, K.
oxytoca and K. variicola were detected in the remedies.
K. pneumoniae is the most pathogenic to humans.
Infections with this bacterium are usually hospital-
acquired. These include urinary tract infection, pneumo-
nia, intra-abdominal infection, bloodstream infection,
meningitis and pyogenic liver abscess [47]. K. pneumoniae
has been reported to posses several intrinsic and acquired
mechanisms which make it resistant to several antimicro-
bial agents [48, 49].
S. enterica was identified in KWTb remedy. It is a rod-
shaped, Gram-negative, flagellated facultative anaerobe.
The bacterium is a medically important pathogen of
both humans and animals. The presence of this bacter-
ium in this remedy is of concern because S. enterica is
known to cause diseases such as gastroenteritis, septi-
caemia and enteric fever clinically [50]. Like many other
infectious diseases, the infection severity of Salmonella
may vary depending on the resistance of individual to
the pathogen, the immune system and the virulence
strain [50].
Enterobacter species are rod-shaped, non-spore-forming,
facultative anaerobes and Gram-negative bacilli bacteria.
Several strains of these bacteria are increasingly been iden-
tified as nosocomial pathogens causing infections in hosts
with impaired immunity [51]. They have been reported to
cause 5 % of hospital-acquired septicemias, 5 % of nosoco-
mial pneumonias, 4 % of nosocomial urinary tract infec-
tions and 10 % of postsurgical peritonitis cases [52]. Skin
and soft tissue infection, endocarditis, intra-abdominal
infection, septic arthritis, osteomyelitis and ophthalmic
infection have been associated with these bacteria. E.
cloacae is ubiquitous in nature, although generally not
known to be an enteric pathogen; it is an opportunistic
pathogen in humans [53, 54]. A wide spectrum of infec-
tions such as the urinary tract, lower respiratory tract,
skin and soft tissue, biliary tract, wounds, intravenous
catheters and the central nervous system have been
associated with Enterobacter cloacae [55].
None of the analysed marketed polyherbal remedies
had any form of food-based tests carried out on them
since they are locally made medicines. This may prob-
ably account for the high discovery of bacterial popula-
tion in the remedies. The results from different findings
conducted on microbial quality of traditional herbal
medicines have been alarming revealing the presence of
pathogenic bacteria and other contaminants in the
herbal therapies [13–15, 17, 56]. Several fatal infectious
outbreaks have been associated with the use of heavily
contaminated raw materials of natural origin with patho-
gens; thus, great efforts are necessary to guarantee constant
and adequate quality [57].
The prevalence of the members of Enterobacteriaceae
in all the herbal remedies was recorded (Fig. 2). Entero-
bacteria are found in nature and are often thought as
indicating faecal contamination. Thus, their presence
could be regarded as an index of the degree of contam-
ination, which may indicate possible presence of harmful
or disease causing organisms [58–60]. Also, higher num-
bers of spore-forming bacteria such as Bacillus sp. and a
few numbers of Clostridium sp. found in the remedies
could be due to the fact that some of these organisms
produce spores which are resistant to harsh processing,
elevated heat and dry conditions, thereby able to survive
for a very long time on the products in dormant states
[26]. Likewise, the members of Paenibacillaceae which
are Gram-positive and are aerobic bacteria that are
related to Bacilli were found in the remedies. Until re-
cently, these organisms were not known to cause human
disease, but now, there are several reports of human
infections caused by some members of this genus [61].
Conclusions
The findings of this study revealed different bacteria
populations in the polyherbal medicines used for the
treatment of tuberculosis in the Eastern Cape Province
of South Africa; this is a cause for concern. Since there
are no legislative criteria governing the microbial quality
of these therapies in South Africa, there is an urgent
need for the Government to take adequate control mea-
sures to set specific standards for quality of these medi-
cines, considering the fact that these medicines are being
taking by immunocompromised individuals. Also, there is
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a need to educate the public as well as the traditional
healers in the Province, that proper hygienic condition
should be maintained in all preparation processes start-
ing from plant collection, processing, packaging and
storage, as well as emphasizing on the implications of
non-compliance to hygienic conditions to both the
consumers and the traditional healers.
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